Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 64.50p 63.00p 66.00p 64.50p 64.50p 64.50p 7,623 07:41:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.7 -7.9 -9.3 - 44.11

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
16/12/2017
08:20
Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 64.50p.
Avacta has a 4 week average price of 64.50p and a 12 week average price of 61p.
The 1 year high share price is 97p while the 1 year low share price is currently 61p.
There are currently 68,393,088 shares in issue and the average daily traded volume is 2,672 shares. The market capitalisation of Avacta is £44,113,541.76.
11/12/2017
11:06
dec2000: Firstly thanks to biotechgeek for his post which hopefully can start a good conversation. And of course his conclusion that the market will decide is also absolutely correct. He approaches the problem from the point of view of production.. and points out that the three main ways of producing affinity ligands are through synthetic chemistry, phage display and in vivo and goes on to point out that Avacta have “simply” made phage display work with a particular type of protein and they have chosen one that is particularly robust. In my belief this is accurate but also undersells what Avacta have achieved and what they are attempting to achieve. In my belief the production issue is not the most important concern.. what is of real significance is what Avacta are hoping to achieve through the use of this technology. The usefulness of any affinity ligand depends partly on the ligand and also what it is attached to and also what you are trying to use it for. In other words there are horses for courses. Indeed that is what Avacta have said : they are not interested in displacing the role of antibodies generally rather finding some alternatives which work better than antibodies in certain circumstances and they have effectively segmented their market into two : diagnostics and research reagents (the so called RxDx market) and the therapeutics market (the Tx market) . In the RxDx market there is massive competition but there are some advantages that Affimers can bring including ease of developing affinity ligands, small molecular size and stability as well as exquisite sensitivity. Of course they compete against phage-display produced antibodies and others, but they do have advantages themselves and other protein scaffolds have not entered the RxDx territory. The proof of this particular pudding does lie in the eating, but they are generating lots of sales leads and have indeed signed a deal with a top 3 diagnostics company… so it can’t be all bad! The question is - can they carve out for themselves a sensibly sized slice of this particular market? With regard to therapeutics, they have deliberately gone for a differentiated strategy which builds on the differences and advantages of Affimers which seems to me to be reasonable. They are using the ability of Affimers to link with themselves to make multimeric molecules which have significant potential uses as T cell recruiters and combination therapies (which might be more therapeutically effective and also more cost effective), they are using the stability of the cystatin molecule to develop drug conjugates with Glythera (also an IP company) which effectively add, say, a poison to the Affimer molecule to be able to selectively kill unwanted cells such as cancer cells; and they are using the simplicity of the cystatin protein and its ease of expression in cells in gene therapy approaches with Moderna. That sounds to me like a sensible approach and not to be denigrated. Whether it works or not of course is the question and why the shares are currently lowly rated. If any of the above are proved to work then the share price will be much higher. As biotechgeek says : the market will decide.
10/12/2017
19:43
lantanatony: Tradernick is spot on and my point is that the likes of Finncap won't be able to raise the required capital. The share price reflects that the market is not convinced. Sadly the take up for Affimers so far has been disappointing and positive news flow in now critical.
08/11/2017
20:54
lantanatony: No support from for the share price from the market or our Brokers even at this low share price. Meanwhile, there seems to be at least one substantial seller about. Therefore, what is the point of our CEO presenting at a Finncap event this month when the hosts are not convinced? I have to ask, what party is insisting on the confidentiality in the deals that Avacta have published? Could it be Avacta are wanting to hide from the deal detail?! Can the whole Big Pharma investing sector be wrong to ignore Avacta? The share price says it all.
04/10/2017
16:11
danatkins: Drewster yes I was thinking on these lines also. Any developments re groundbreaking therapeutics would multiple the share price and very quickly. Also another reason why Avacta could be bought. Just my opinion. Personally of any success I'd like to see expansion of the co.
04/10/2017
11:27
the drewster: One day it will either give up, be sold in a fire sale, or be ten to one hundred times the share price. Risk reward profile is for each individual speculator to decide.
24/8/2017
15:45
the drewster: Some history ... 2006 issue 4.5m shares at 225 on readmission - Mkt Cap £14.5m 2008 issued shares at prices above 500 to buy Oxford Medical Diagnostics ltd ... market cap then around £45m in March 2008 Subsequent cash raising activity: £2m @ 150 October 09 £1.95m @ 105 January '11 £4.7m @ 55 July '13 £10m @ 110 May '14 £22m @ 125 July '15 Weighted average, £40.65m @ 105 Update end July '17, that cash is c.£13m. Share price around 75p and Market Cap at about £52m
02/8/2017
21:53
lantanatony: Lentjes Are you just trying to push the share price down,with a view to some good news and pick up a few more on the cheap? I my view Alistair Smith is just promoting the company in the best interests of the shareholders.
04/12/2016
09:27
wan: I note we now have the reason for the recent drop in the share price, in the form of a relatively large sell trade at 75p. I don't talk about the share price very often, but to perhaps put some perspective across regarding Avacta's share price performance, emerging U.S. biotech firms are down 39 percent this year and their European counterparts are down by 27 percent (and I appreciate that that probable doesn't make anyone feel any better). The main reason driving this under-performance, relative to the wider equity markets, is that drug pricing is weighing on investors minds and it has shifted sentiment. However, with large pharma showing strong interest in preclinical assets, it has been a good year for some companies with early stage assets to sell. Indeed, news elsewhere shows that large pharma is also very interested in alternatives to antibodies and it also continues to demonstrate their strong interest in preclinical assets - Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Peptides tend to be unpopular because they’re usually less specific than antibodies, although Amcure in Germany is also relying on them to treat cancer. Although the bicyclic peptide technology hasn’t proved itself worthy in the clinic yet, AstraZeneca seems to be attracted by the myriad advantages it offers. For Bicycle Therapeutics, this agreement means an expansion into new disease areas, which were mostly restricted to oncology so far. Full story - http://labiotech.eu/bicycle-therapeutics-astrazeneca/ The AstraZeneca deal with Bicycle is interesting in terms of the development stage of Bicycle. It is also perhaps more than interesting in terms of it being about an alternative to antibodies, which we know are expensive to produce (not to mention other issues). So this brings me back to drug pricing, and it is interesting that if a peptide works in a particular application then it could be attractive because it is easy to produce and subsequently much cheaper than antibodies. It will thus be interesting to see if acquiring or partnering assets that can ultimately reduce the cost of drugs becomes a trend. If so, then Avacta could be in an even better place than some are currently assuming. My research indicates that Affimers, being proteins, have larger interaction areas, have a greater range of conformations and higher affinities than peptides, hence the range of collaborations to date. So, while Bicycle's offering has clearly caught attention (another example of British success....well done!), it's not difficult to imagine that Affimers are attracting interest beyond the already declared interest coming from affinity separation, immunoassays and lateral flow diagnostics players. I appreciate though that some investors are only interested in substance i.e. something tangible and meaningful in terms of cash, as opposed to promises. But Avacta has attracted some very interesting and talented people (including collaborations), and such individuals don't usually align themselves to technologies or small companies without very good reason. Whilst some on here are inclined to describe Avacta as a failure waiting to happen, I am far more inclined to describe Avacta as another British success waiting to happen! We should champion British companies, especially ones that could also make a significant difference to peoples lives. Staying with British; I note that whilst I was away recently a sizeable UK focused fund is being created - Battle Against Cancer joins Wellcome to be £1bn champion Battle Against Cancer Investment Trust plans to team up with Wellcome Trust and become national champion in healthcare research The £483 million company today announced a big change in direction, unveiling plans to deepen its involvement in cancer research and biotechnology investment. It will potentially more than double in size to £1 billion and will gradually wind down its investments in alternative funds. ‘The same logic has given rise to this transaction, which will create a national champion of life science investing and accelerate the achievement of our aim: to win the battle against cancer and to create great returns for our investors at the same time.’ ‘This represents a major change in strategy for Bacit,’ said Numis analyst Ewan Lovett-Turner. ‘The tie-up with Wellcome Trust is an interesting development that looks set to create a sizeable listed company to support investment in UK life sciences. Full story - http://citywire.co.uk/money/battle-against-cancer-joins-wellcome-to-be-1bn-champion/a966356 And the following also stood out - £226 million UK investment in cancer research announced 1st December Cancer Research UK has announced the largest investment to date into its network of Centres across the UK. £190 million has been committed to 13 Cancer Research UK Centres over the next five years. “I’m particularly pleased that our international panel of experts, which renewed these Centres, stated repeatedly their view that there is no other network like this, of this quality, anywhere else in the world. “This is an exciting time for cancer research. Emerging treatments like immunotherapy are radically changing the field, we are increasingly able to tailor more treatments to individual patients, and advances in technology mean we can collect and share more research data than ever before. Full story - http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-12-01-ps226-million-uk-investment-in-cancer-research-announced
01/12/2016
10:32
dec2000: Clearly the market knows well in advance (24 hours) of us "normal shareholders" about RNS messages etc. However the drop in share price does not seem to have any fundamental support or reason. As I mentioned yesterday the drop in share price does not even seem to be linked to any significant share sale. The strategic update just released confirms everything we know about the company. There are no surprises. I e mailed Alastair Smith and whilst he cannot comment on share movements specifically, he expressed his "frustration" at yesterday's sudden movement and confirmed the steady progress of the company. Overall I believe the best conclusion is that this is an attempt to manipulate the share price (which often happens for small companies) and the right response is to sit tight and even use it as a buying opportunity
30/11/2016
18:41
dec2000: Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months! Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200. On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05. Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP. 12 Month Share Chart For Avacta Group PLC LON:AVCT In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00. The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02. Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171216 22:37:38